Tilray Brands (TLRY) Non Operating Investment Income (2019 - 2026)
Tilray Brands' (TLRY) quarterly Non Operating Investment Income came in at -$4.1 million in Q1 2026, up 24.31% YoY from -$3.3 million in Q1 2025, and down 1100.87% on a QoQ basis from -$345000.0 in Q4 2025.
Tilray Brands (TLRY) Non Operating Investment Income (2019 - 2026) Analysis & Trends
Tilray Brands (TLRY) has 8 years of Non Operating Investment Income data on file, last reported at -$4.1 million in Q1 2026.
- Quarterly Non Operating Investment Income rose 24.31% year-over-year to -$4.1 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was -$9.9 million (down 80.19% YoY) and the FY2022 annual result came in at -$6.7 million, down 186.44% from the prior year.
- Non Operating Investment Income fell to -$4.1 million in Q1 2026, from -$345000.0 in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $459000.0 in Q4 2023 to a low of -$5.5 million in Q1 2025.
- A 5-year average of -$1.2 million and a median of -$345000.0 in 2025 frame the typical range for Non Operating Investment Income.
- The widest YoY moves for Non Operating Investment Income: up 200.0% in 2025, down 16687.88% in 2025.
- Tracing TLRY's Non Operating Investment Income over 5 years: stood at -$596000.0 in 2022, then surged by 177.01% to $459000.0 in 2023, then plunged by 105.88% to -$27000.0 in 2024, then tumbled by 1177.78% to -$345000.0 in 2025, then tumbled by 1100.87% to -$4.1 million in 2026.
- The last three Non Operating Investment Income figures came in at -$4.1 million (Q1 2026), -$345000.0 (Q4 2025), and $39000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Tilray Brands | 512.75 Mn | 278.12 Mn | 90.52 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -4.14 Mn |
| Feb 28, 2026 | -4.14 Mn |
| Nov 30, 2025 | -345,000.00 |
| Nov 30, 2025 | -345,000.00 |
| Aug 31, 2025 | 39,000.00 |
| Aug 31, 2025 | 39,000.00 |
| Feb 28, 2025 | -5.47 Mn |
| Feb 28, 2025 | -5.47 Mn |
| Nov 30, 2024 | -27,000.00 |
| Nov 30, 2024 | -27,000.00 |
| Aug 31, 2024 | -39,000.00 |
| Aug 31, 2024 | -39,000.00 |
| Feb 29, 2024 | 33,000.00 |
| Feb 29, 2024 | 33,000.00 |
| Nov 30, 2023 | 459,000.00 |
| Nov 30, 2023 | 459,000.00 |
| Feb 28, 2023 | -925,000.00 |
| Feb 28, 2023 | -925,000.00 |
| Nov 30, 2022 | -596,000.00 |
| Nov 30, 2022 | -596,000.00 |